- Trials with a EudraCT protocol (58)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
58 result(s) found for: Oxidation.
Displaying page 1 of 3.
EudraCT Number: 2018-003283-31 | Sponsor Protocol Number: NL67170.068.18 | Start Date*: 2019-03-13 |
Sponsor Name:School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University | ||
Full Title: MaasFlex: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Ox... | ||
Medical condition: Study to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003176-13 | Sponsor Protocol Number: 67133 | Start Date*: 2019-02-18 |
Sponsor Name:Maastricht University | ||
Full Title: Lowering Branched-Chain Amino Acids as a New Strategy to Treat Diabetes | ||
Medical condition: type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-003750-10 | Sponsor Protocol Number: NA | Start Date*: 2005-09-12 |
Sponsor Name:VästraGötaland | ||
Full Title: Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism | ||
Medical condition: Chronic treatment with glucocorticoids (GCs) regardless of indication leads to marked protein catabolism that causes substantial debilitation which includes muscle wasting, weakness, skin fragility... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001539-10 | Sponsor Protocol Number: UX007-CL302 | Start Date*: 2022-12-27 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient... | |||||||||||||
Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000322-19 | Sponsor Protocol Number: UX007-CL202 | Start Date*: 2016-06-06 |
Sponsor Name:Ultragenyx Pharmaceutial Inc. | ||
Full Title: An Open-label Long-Term Safety and Efficacy Extension Study in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies | ||
Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2010-018531-17 | Sponsor Protocol Number: TRED012010 | Start Date*: 2010-06-25 |
Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | ||
Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function. | ||
Medical condition: Hypercholesterolaemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000956-32 | Sponsor Protocol Number: 20022012 | Start Date*: 2012-06-28 |
Sponsor Name:St. Antonius Ziekenhuis | ||
Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients | ||
Medical condition: Morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000808-16 | Sponsor Protocol Number: C11palmitatmetformin | Start Date*: 2013-03-27 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effects of metformin on hepatic free fatty acid metabolism in type 2 diabetes asssessed by positron emission tomography | |||||||||||||
Medical condition: Type 2 diabetes and dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006704-27 | Sponsor Protocol Number: Bezafibrate | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet | |||||||||||||
Full Title: Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle | |||||||||||||
Medical condition: Evaluation of the effect of Bezafibrate on muscle metabolism during exercise in patients with VLCAD and CPT II deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004830-14 | Sponsor Protocol Number: UX007-CL201 | Start Date*: 2014-02-26 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
Medical condition: Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004373-10 | Sponsor Protocol Number: p08- | Start Date*: 2008-04-08 | |||||||||||
Sponsor Name:Top institute of Pharmaceutical Research | |||||||||||||
Full Title: The effect of short term Topiramate treatment on insulin secretion, glucose- and lipid metabolism in obese women | |||||||||||||
Medical condition: Obesity Diabetes Mellitus Metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002045-36 | Sponsor Protocol Number: | Start Date*: 2016-11-17 |
Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||
Full Title: Lifestyle induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH) | ||
Medical condition: Non-alcoholic steatohepatitis (NASH) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-002436-82 | Sponsor Protocol Number: EC11-441 | Start Date*: 2012-12-13 |
Sponsor Name:Isabel Pinilla Lozano | ||
Full Title: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa | ||
Medical condition: To evaluate the sleep quality in patients with Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002915-17 | Sponsor Protocol Number: FIM-EOX-2016-01 | Start Date*: 2016-11-03 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS) | |||||||||||||
Full Title: Impact on oxidative stress of novel analogues of insulin in people with type 1 diabetes. Low- intervention clinical trial. Ineox Study | |||||||||||||
Medical condition: DIABETES TYPE 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002263-15 | Sponsor Protocol Number: LIXISL07016 | Start Date*: 2014-10-10 |
Sponsor Name:sanofi aventis S.p.A | ||
Full Title: Effects of GLP-1 Receptor Agonist Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients | ||
Medical condition: Effect of GLP-1 receptor agonist lixisenatide on post-prandial lipid profile in obese patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-003011-46 | Sponsor Protocol Number: ASOKLIF 0603/ST | Start Date*: 2006-09-06 |
Sponsor Name:Dr. Olaf Stanger | ||
Full Title: Klinische Studie zur Überprüfung des Stellenwerts einer perioperativen Verabreichung der Vitamine E und C und/oder von Omega-3-Fettsäuren bei der Verminderung des Reperfusionsschadens nach Herzoper... | ||
Medical condition: aortokoronare Bypassoperation bei einer geschätzten Dauer der extrakorporalen Zirkulation (EKZ) zwischen 20 und 60 Minuten | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004370-96 | Sponsor Protocol Number: LG-TCS-AD | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:Jacob Pontoppidan Thyssen | |||||||||||||
Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005585-32 | Sponsor Protocol Number: 111111733104 | Start Date*: 2016-06-24 | |||||||||||
Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen | |||||||||||||
Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial | |||||||||||||
Medical condition: Obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000823-15 | Sponsor Protocol Number: DIASA3 | Start Date*: 2019-10-18 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Glucose metabolism in South Asian women with impaired glucose tolerance or impaired fasting glucose. DIAbetes in South Asians – DIASA 3 A 12-week intervention trial with oral antidiabetic medicati... | |||||||||||||
Medical condition: Pre-diabetes in women of South Asian ethnicity. Women of South Asian ethnicity with previous gestational diabetes, where pre-diabetes in the form of impaired glucose tolerance or impaired fasting ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012707-26 | Sponsor Protocol Number: Acetilcisteina-Ocronosi-SI/2009 | Start Date*: 2010-05-27 |
Sponsor Name:AZIENDA OSPEDALIERA SENESE | ||
Full Title: THERAPEUTIC EFFECTIIVENESS OF N-ACETYL-CYSTEINE AND ASCORBIC ACID IN PATIENTS WITH ALKAPTONURIA-OCHRONOSIS | ||
Medical condition: patient affected by alkaptonuria-ocronosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
